Diversified Trust Co Takes $958,000 Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Diversified Trust Co acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,916 shares of the medical research company's stock, valued at approximately $958,000.

Several other institutional investors also recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in shares of Bio-Rad Laboratories by 24.3% in the 4th quarter. GAMMA Investing LLC now owns 665 shares of the medical research company's stock worth $218,000 after purchasing an additional 130 shares in the last quarter. Principal Financial Group Inc. grew its position in Bio-Rad Laboratories by 95.6% during the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock valued at $14,836,000 after acquiring an additional 21,669 shares during the last quarter. Retirement Systems of Alabama raised its stake in shares of Bio-Rad Laboratories by 416.9% during the third quarter. Retirement Systems of Alabama now owns 23,260 shares of the medical research company's stock worth $7,782,000 after acquiring an additional 18,760 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Bio-Rad Laboratories by 17.0% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 28,523 shares of the medical research company's stock worth $9,543,000 after acquiring an additional 4,138 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at $878,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Down 0.7 %

BIO stock traded down $2.52 on Friday, reaching $341.86. The company's stock had a trading volume of 132,665 shares, compared to its average volume of 130,477. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The firm has a market cap of $9.57 billion, a PE ratio of -12.51 and a beta of 0.90. The business has a fifty day simple moving average of $339.69 and a two-hundred day simple moving average of $326.93.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.16 by $0.85. The company had revenue of $649.70 million during the quarter, compared to analysts' expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.33 EPS. As a group, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Citigroup lifted their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, Royal Bank of Canada raised their price target on Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an "outperform" rating in a research report on Monday, December 9th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.